1
|
Rahmani F, Jindal S, Raji CA, Wang W, Nazeri A, Perez-Carrillo GG, Miller-Thomas MM, Graner P, Marechal B, Shah A, Zimmermann M, Chen CD, Keefe S, LaMontagne P, Benzinger TLS. Validity Assessment of an Automated Brain Morphometry Tool for Patients with De Novo Memory Symptoms. AJNR Am J Neuroradiol 2023; 44:261-267. [PMID: 36797031 PMCID: PMC10187815 DOI: 10.3174/ajnr.a7790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Accepted: 01/09/2023] [Indexed: 02/18/2023]
Abstract
BACKGROUND AND PURPOSE Automated volumetric analysis of structural MR imaging allows quantitative assessment of brain atrophy in neurodegenerative disorders. We compared the brain segmentation performance of the AI-Rad Companion brain MR imaging software against an in-house FreeSurfer 7.1.1/Individual Longitudinal Participant pipeline. MATERIALS AND METHODS T1-weighted images of 45 participants with de novo memory symptoms were selected from the OASIS-4 database and analyzed through the AI-Rad Companion brain MR imaging tool and the FreeSurfer 7.1.1/Individual Longitudinal Participant pipeline. Correlation, agreement, and consistency between the 2 tools were compared among the absolute, normalized, and standardized volumes. Final reports generated by each tool were used to compare the rates of detection of abnormality and the compatibility of radiologic impressions made using each tool, compared with the clinical diagnoses. RESULTS We observed strong correlation, moderate consistency, and poor agreement between absolute volumes of the main cortical lobes and subcortical structures measured by the AI-Rad Companion brain MR imaging tool compared with FreeSurfer. The strength of the correlations increased after normalizing the measurements to the total intracranial volume. Standardized measurements differed significantly between the 2 tools, likely owing to differences in the normative data sets used to calibrate each tool. When considering the FreeSurfer 7.1.1/Individual Longitudinal Participant pipeline as a reference standard, the AI-Rad Companion brain MR imaging tool had a specificity of 90.6%-100% and a sensitivity of 64.3%-100% in detecting volumetric abnormalities. There was no difference between the rate of compatibility of radiologic and clinical impressions when using the 2 tools. CONCLUSIONS The AI-Rad Companion brain MR imaging tool reliably detects atrophy in cortical and subcortical regions implicated in the differential diagnosis of dementia.
Collapse
Affiliation(s)
- F Rahmani
- From the Mallinckrodt Institute of Radiology, Division of Neuroradiology (F.R., S.J., C.A.R., W.W., A.N., G.G.P.-C., M.M.M.-T., C.D.C., S.K., P.L., T.L.S.B.)
- Charles F. and Joanne Knight Alzheimer Disease Research Center (F.R., S.J., C.A.R., W.W., A.N., C.D.C., T.L.S.B.), Washington University in St. Louis, St. Lous, Missouri
| | - S Jindal
- From the Mallinckrodt Institute of Radiology, Division of Neuroradiology (F.R., S.J., C.A.R., W.W., A.N., G.G.P.-C., M.M.M.-T., C.D.C., S.K., P.L., T.L.S.B.)
- Charles F. and Joanne Knight Alzheimer Disease Research Center (F.R., S.J., C.A.R., W.W., A.N., C.D.C., T.L.S.B.), Washington University in St. Louis, St. Lous, Missouri
| | - C A Raji
- From the Mallinckrodt Institute of Radiology, Division of Neuroradiology (F.R., S.J., C.A.R., W.W., A.N., G.G.P.-C., M.M.M.-T., C.D.C., S.K., P.L., T.L.S.B.)
- Charles F. and Joanne Knight Alzheimer Disease Research Center (F.R., S.J., C.A.R., W.W., A.N., C.D.C., T.L.S.B.), Washington University in St. Louis, St. Lous, Missouri
| | - W Wang
- From the Mallinckrodt Institute of Radiology, Division of Neuroradiology (F.R., S.J., C.A.R., W.W., A.N., G.G.P.-C., M.M.M.-T., C.D.C., S.K., P.L., T.L.S.B.)
- Charles F. and Joanne Knight Alzheimer Disease Research Center (F.R., S.J., C.A.R., W.W., A.N., C.D.C., T.L.S.B.), Washington University in St. Louis, St. Lous, Missouri
| | - A Nazeri
- From the Mallinckrodt Institute of Radiology, Division of Neuroradiology (F.R., S.J., C.A.R., W.W., A.N., G.G.P.-C., M.M.M.-T., C.D.C., S.K., P.L., T.L.S.B.)
- Charles F. and Joanne Knight Alzheimer Disease Research Center (F.R., S.J., C.A.R., W.W., A.N., C.D.C., T.L.S.B.), Washington University in St. Louis, St. Lous, Missouri
| | - G G Perez-Carrillo
- From the Mallinckrodt Institute of Radiology, Division of Neuroradiology (F.R., S.J., C.A.R., W.W., A.N., G.G.P.-C., M.M.M.-T., C.D.C., S.K., P.L., T.L.S.B.)
| | - M M Miller-Thomas
- From the Mallinckrodt Institute of Radiology, Division of Neuroradiology (F.R., S.J., C.A.R., W.W., A.N., G.G.P.-C., M.M.M.-T., C.D.C., S.K., P.L., T.L.S.B.)
| | - P Graner
- Siemens Medical Solutions (P.G., B.M., M.Z.), Malvern, Pennsylvania
- Advanced Clinical Imaging Technology (P.G., B.M., M.Z.), Siemens Healthcare, Lausanne, Switzerland
- Department of Radiology (P.G., B.M., M.Z.), Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- LTS5, École Polytechnique Fédérale de Lausanne (P.G., B.M., A.S., M.Z.), Lausanne, Switzerland
- Siemens Healthcare (P.G., B.M., M.Z.), Erlangen, Germany
| | - B Marechal
- Siemens Medical Solutions (P.G., B.M., M.Z.), Malvern, Pennsylvania
- Advanced Clinical Imaging Technology (P.G., B.M., M.Z.), Siemens Healthcare, Lausanne, Switzerland
- Department of Radiology (P.G., B.M., M.Z.), Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- LTS5, École Polytechnique Fédérale de Lausanne (P.G., B.M., A.S., M.Z.), Lausanne, Switzerland
- Siemens Healthcare (P.G., B.M., M.Z.), Erlangen, Germany
| | - A Shah
- LTS5, École Polytechnique Fédérale de Lausanne (P.G., B.M., A.S., M.Z.), Lausanne, Switzerland
| | - M Zimmermann
- Siemens Medical Solutions (P.G., B.M., M.Z.), Malvern, Pennsylvania
- Advanced Clinical Imaging Technology (P.G., B.M., M.Z.), Siemens Healthcare, Lausanne, Switzerland
- Department of Radiology (P.G., B.M., M.Z.), Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- LTS5, École Polytechnique Fédérale de Lausanne (P.G., B.M., A.S., M.Z.), Lausanne, Switzerland
- Siemens Healthcare (P.G., B.M., M.Z.), Erlangen, Germany
| | - C D Chen
- From the Mallinckrodt Institute of Radiology, Division of Neuroradiology (F.R., S.J., C.A.R., W.W., A.N., G.G.P.-C., M.M.M.-T., C.D.C., S.K., P.L., T.L.S.B.)
- Charles F. and Joanne Knight Alzheimer Disease Research Center (F.R., S.J., C.A.R., W.W., A.N., C.D.C., T.L.S.B.), Washington University in St. Louis, St. Lous, Missouri
| | - S Keefe
- From the Mallinckrodt Institute of Radiology, Division of Neuroradiology (F.R., S.J., C.A.R., W.W., A.N., G.G.P.-C., M.M.M.-T., C.D.C., S.K., P.L., T.L.S.B.)
| | - P LaMontagne
- From the Mallinckrodt Institute of Radiology, Division of Neuroradiology (F.R., S.J., C.A.R., W.W., A.N., G.G.P.-C., M.M.M.-T., C.D.C., S.K., P.L., T.L.S.B.)
| | - T L S Benzinger
- From the Mallinckrodt Institute of Radiology, Division of Neuroradiology (F.R., S.J., C.A.R., W.W., A.N., G.G.P.-C., M.M.M.-T., C.D.C., S.K., P.L., T.L.S.B.)
- Charles F. and Joanne Knight Alzheimer Disease Research Center (F.R., S.J., C.A.R., W.W., A.N., C.D.C., T.L.S.B.), Washington University in St. Louis, St. Lous, Missouri
| |
Collapse
|
5
|
Roostaei T, Nazeri A, Felsky D, De Jager PL, Schneider JA, Pollock BG, Bennett DA, Voineskos AN. Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease. Mol Psychiatry 2017; 22:287-295. [PMID: 27021820 PMCID: PMC5042808 DOI: 10.1038/mp.2016.35] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2015] [Revised: 02/15/2016] [Accepted: 02/17/2016] [Indexed: 12/18/2022]
Abstract
The lack of strong association between brain beta-amyloid deposition and cognitive impairment has been a challenge for the Alzheimer's disease (AD) field. Although beta-amyloid is necessary for the pathologic diagnosis of AD, it is not sufficient to make the pathologic diagnosis or cause dementia. We sought to identify the genetic modifiers of the relation between cortical beta-amyloid burden (measured using [18F]Florbetapir-PET) and cognitive dysfunction (measured using ADAS-cog) by conducting a genome-wide interaction study on baseline data from participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) phases GO/2 (n=678). Near genome-wide significant interaction effect was observed for rs73069071 within the IAPP (amylin) and SLCO1A2 genes (P=6.2 × 10-8). Congruent results were found using data from participants followed up from ADNI-1 (Pone-tailed=0.028, n=165). Meta-analysis across ADNI-GO/2 and ADNI-1 revealed a genome-wide significant interaction effect (P=1.1 × 10-8). Our results were further supported by similar interaction effects on temporal lobe cortical thickness (whole-brain voxelwise analysis: familywise error corrected P=0.013) and longitudinal changes in ADAS-cog score and left middle temporal thickness and amygdalar volume (Pone-tailed=0.026, 0.019 and 0.003, respectively). Using postmortem beta-amyloid immunohistochemistry data from 243 AD participants in the Religious Orders Study and Memory and Aging Project, we also observed similar rs73069071-by-beta-amyloid deposition interaction effect on global cognitive function (Pone-tailed=0.005). Our findings provide insight into the complexity of the relationship between beta-amyloid burden and AD-related cognitive impairment. Although functional studies are required to elucidate the role of rs73069071 in AD pathophysiology, our results support the recently growing evidence on the role of amylin in AD.
Collapse
Affiliation(s)
- T Roostaei
- Kimel Family Translational Imaging-Genetics Laboratory, Research Imaging Centre, Campbell Family Mental Health Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - A Nazeri
- Kimel Family Translational Imaging-Genetics Laboratory, Research Imaging Centre, Campbell Family Mental Health Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - D Felsky
- Kimel Family Translational Imaging-Genetics Laboratory, Research Imaging Centre, Campbell Family Mental Health Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Institute of Medical Science, University of Toronto, Toronto, ON, Canada
| | - P L De Jager
- Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, MA, USA
- Department of Neurology, Harvard Medical School, Boston, MA, USA
- Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - J A Schneider
- Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA
- Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA
- Department of Pathology, Rush University Medical Center, Chicago, IL, USA
| | - B G Pollock
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Geriatric Psychiatry Division, Campbell Family Mental Health Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
| | - D A Bennett
- Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA
- Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA
| | - A N Voineskos
- Kimel Family Translational Imaging-Genetics Laboratory, Research Imaging Centre, Campbell Family Mental Health Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Institute of Medical Science, University of Toronto, Toronto, ON, Canada
- Underserved Populations Program, Centre for Addiction and Mental Health, Toronto, ON, Canada
| | | |
Collapse
|